Molecular Subtype
ALK-Positive Lung Non-Small Cell Carcinoma
CI-CAN-00007197Explore in graph →
10 active trials1 approved drugs
- NCIt
- C215346
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00007197Explore in graph →
Clinical trials
25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05987956 | Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Medicine Invention Design, IncINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07491497 | A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC | recruiting | Phase 1 / Phase 2 | 160 | TRIANA Biomedicines, Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07771764 | A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 30 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07750704 | Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC | not yet recruiting | Phase 2 | 153 | Guangdong Association of Clinical TrialsOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06092086 | Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC | recruiting | Phase 2 | 126 | Guangdong Association of Clinical TrialsOTHER | 1 | Oct 23, 2023 | clinicaltrials |
Data updated 16 hours agoSource updated Sep 29, 2026source: clinicaltrials